Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMXMAJA)

Drug Name

Fosgonimeton Drug Info

Synonyms

Fosgonimeton; Fosgonimeton [INN]; Fosgonimeton [USAN]; UNII-H91OA9858J; H91OA9858J; 2093305-05-4; Fosgonimeton [USAN:INN]; ATH-1017; NDX-1017; WHO 11782; L-Isoleucinamide, O-(phosphono-kappaO)-N-(1-oxohexyl)-L-tyrosyl-N-(6-amino-6-oxohexyl)-,; ATH-1017 FREE ACID; NDX-1017 FREE ACID; CHEMBL5095419; AKOS040757261; HY-132814; CS-0204081; L-Isoleucinamide, O-(phosphono-kappaO)-N-(1-oxohexyl)-L-tyrosyl-N-(6-amino-6-oxohexyl)-; dihydrogen 4-[(2S)-3-({(2S,3S)-1-[(6-amino-6-oxohexyl)amino]-3-methyl-1-oxopentan-2-yl}amino)-2-hexanamido-3-oxopropyl]phenyl phosphate

Indication

Disease Entry	ICD 11	Status	REF
Alzheimer disease	8A20	Phase 2/3	[1]
Parkinson disease	8A00.0	Phase 2	[2]

Cross-matching ID

PubChem CID: 156596375
TTD Drug ID: DMXMAJA

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting HGF/Met signaling pathway (HGF/Met pathway)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Crizotinib	DM4F29C	Non-small-cell lung cancer	2C25.Y	Approved	[4]
SAIT301	DMLU6J0	Nasopharyngeal carcinoma	2B6B	Investigative	[5]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
HGF/Met signaling pathway (HGF/Met pathway)	TTKA5LP	NOUNIPROTAC	Not Available	[3]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT04886063) Open-Label Extension of Studies ATH-1017-AD-0201 and ATH-1017-AD-0202 in Subjects With Mild to Moderate Alzheimer's Disease. U.S.National Institutes of Health.
2	ClinicalTrials.gov (NCT04831281) A Randomized, Placebo-Controlled, Double-Blind Study of ATH-1017 Treatment in Subjects With Parkinson's Disease Dementia or Dementia With Lewy Bodies. U.S.National Institutes of Health.
3	Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Positive Modulator of HGF/MET, Fosgonimeton, in Healthy Volunteers and Subjects with Alzheimer's Disease: Randomized, Placebo-Controlled, Double-Blind, Phase I Clinical Trial. J Alzheimers Dis. 2022;86(3):1399-1413.
4	Met tyrosine kinase inhibitor, PF-2341066, suppresses growth and invasion of nasopharyngeal carcinoma.Drug Des Devel Ther. 2015 Aug 26;9:4897-907.
5	Nasopharyngeal carcinoma: Current treatment options and future directions. J Nasopharyng Carcinoma, 2014, 1(16): e16.